1 documents found
Information × Registration Number 0221U106198, 0120U104687 , R & D reports Title Study of the therapeutic effectiveness and safety of new equivalents of the dermis with the inclusion of a composite (the drug izatizon and the cytokine EMAP II) for the treatment of traumatic skin lesions popup.stage_title Head Lukash Liubov L., Доктор біологічних наук Registration Date 04-11-2021 Organization Institute of Molecular Biology and Genetics of NAS of Ukraine popup.description2 The main goal of the project is to create a new biotechnological product: dermal equivalents with the inclusion of a complex of biologically active substances synthesized by stem cells and a pharmaceutical composite (drug isatizon and cytokine EMAP II), as well as studies of their therapeutic efficacy and safety in vivo. The task of stage № 1: creation and development of samples of new equivalents of the dermis and comparative analysis of their therapeutic efficacy in vivo. Research methods: in vitro culture, experiments on model animals in vivo, pathophysiological, biochemical, statistical. A new biotechnological product (dermis equivalent) has been created, which has no world analogues and can be offered for the treatment of traumatic skin injuries. Samples of new dermal equivalents based on a soft hydrogel with the inclusion of a complex of biologically active substances synthesized by stem cells and a pharmaceutical composite (the drug isatizon and the cytokine EMAP II) have been developed. It was found that they promote faster and more effective healing of burn wounds in experimental animals compared to the corresponding controls. At the same time, there were no signs of their acute toxicity when applied externally. Therefore, next year it is advisable to conduct special preclinical studies to determine the safety of a new biotechnological product for further clinical trials and implementation in practical medicine. Product Description popup.authors Zaika Leonid A. Kolomiiets Lesia A. Kornelyuk Olexander Ivanovych Macewicz Larysa Leonidivna Papuga Alexander Yevgeniiovych Ruban Tetyana P. popup.nrat_date 2021-11-04 Close
R & D report
Head: Lukash Liubov L.. Study of the therapeutic effectiveness and safety of new equivalents of the dermis with the inclusion of a composite (the drug izatizon and the cytokine EMAP II) for the treatment of traumatic skin lesions. (popup.stage: ). Institute of Molecular Biology and Genetics of NAS of Ukraine. № 0221U106198
1 documents found

Updated: 2026-03-19